CoChat

Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen

Open access
Poole, Andrew, Karuppiah, Vijaykumar, Hartt, Annabelle, Haidar, Jaafar N., Moureau, Sylvie, Dobrzycki, Tomasz, Hayes, Conor, Rowley, Christopher, Dias, Jorge, Harper, Stephen, Barnbrook, Keir, Hock, Miriam, Coles, Charlotte, Yang, Wei, Aleksic, Milos, Lin, Aimee Bence, Robinson, Ross, Dukes, Joe D., Liddy, Nathaniel, Van der Kamp, Marc, Plowman, Gregory D., Vuidepot, Annelise, Cole, David K., Whale, Andrew D., Chillakuri, Chandramouli · 2022 · Nature Communications
Cited by 110

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Neoantigens derived from somatic mutations are specific to cancer cells and are ideal targets for cancer immunotherapy. KRAS is the most frequently mutated oncogene and drives the pathogenesis of several cancers. Here we show the identification and development of an affinity-enhanced T cell receptor (TCR) that recognizes a peptide derived from the most common KRAS mutant, KRAS G12D, presented in the context of HLA-A*11:01. The affinity of the engineered TCR is increased by over one million-fold yet fully able to distinguish KRAS G12D over KRAS WT. While crystal structures reveal few discernible differences in TCR interactions with KRAS WT versus KRAS G12D, thermodynamic analysis and molecular dynamics simulations reveal that TCR specificity is driven by differences in indirect electrostatic interactions. The affinity enhanced TCR, fused to a humanized anti-CD3 scFv, enables selective killing of cancer cells expressing KRAS G12D. Our work thus reveals a molecular mechanism that drives TCR selectivity and describes a soluble bispecific molecule with therapeutic potential against cancers harboring a common shared neoantigen.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-022-32811-1

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 110

Metadata

Authors
Poole, A., Karuppiah, V., Hartt, A., Haidar, J. N., Moureau, S., Dobrzycki, T., Hayes, C., Rowley, C., Dias, J., Harper, S., Barnbrook, K., Hock, M., Coles, C., Yang, W., Aleksic, M., Lin, A. B., Robinson, R., Dukes, J. D., Liddy, N., Van der Kamp, M., Plowman, G. D., Vuidepot, A., Cole, D. K., Whale, A. D., & Chillakuri, C.
Venue
Nature Communications
Published
2022-09-10
Volume
13
Issue
1
Pages
5333-5333
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4295514007
Cited by
110
References
18
FWCI
7.52
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen. https://app.cochat.ai/papers/10.1038/s41467-022-32811-1
The paper
Poole, A., Karuppiah, V., Hartt, A., Haidar, J. N., Moureau, S., Dobrzycki, T., Hayes, C., Rowley, C., Dias, J., Harper, S., Barnbrook, K., Hock, M., Coles, C., Yang, W., Aleksic, M., Lin, A. B., Robinson, R., Dukes, J. D., Liddy, N., . . . Chillakuri, C. (2022). Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen. Nature Communications. https://doi.org/10.1038/s41467-022-32811-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.